Board of Directors
STUART M. ESSIG, PH.D. currently serves as managing director of Prettybrook Partners LLC, investing in medical technology companies.
He has been Integra LifeSciences Corporation's chairman of the Board of Directors since 2012, and a director since he joined Integra in 1997. He served as the company’s chief executive officer from 1997 to 2012, building Integra into a global surgical products leader. During Stuart’s 20-year tenure with the company, Integra has grown revenues from $15 million to over $1 billion.
Before joining Integra, Dr. Essig was managing director of the medical technology practice at Goldman, Sachs & Co. He had 10 years of broad healthcare experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients.
Dr. Essig has chaired audit, compensation and nominating and governance committees, served as lead director, and participated in CEO succession processes on the boards of numerous public companies, ranging in size from several hundred million dollars to almost $30 billion in levered market capitalization.
In addition to Integra, Dr. Essig currently serves on the Board of Directors of SeaSpine Holdings Corporation (NASDAQ:SPNE) and Owens & Minor, Inc. (NYSE:OMI). He is also the chairman of the Board of Directors of private-equity backed Breg, Inc. Dr. Essig is an executive-in-residence at Cardinal Partners and a venture partner at Wellington Partners Advisory AG, both venture capital firms. He also serves as a senior advisor to TowerBrook Capital Partners and Water Street Healthcare Partners. Dr. Essig is a founding investor member of Tigerlabs, a Princeton-based business accelerator. He serves on the Leadership Counsel of the Princeton University School of Engineering and Applied Sciences, and the NACD Compensation Committee Chair Advisory Counsel.
Dr. Essig previously served on the Board of Directors of St. Jude Medical Corporation (NYSE:SJM) from 1999 to 2017, prior to its sale to Abbott Corporation. From 2005 until 2008, he served on the Board of Directors of Zimmer Holdings, Inc. (NYSE:ZMH), and from 1998 to 2002, he served on the Board of Directors of Vital Signs, Inc. (NASDAQ:VITL). Dr. Essig also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association. He is also involved in several non-profit charitable organizations, including from time to time serving on their boards. Since 2012, Dr. Essig has served on the Board of Directors of Trenton-area non-profit organization, Isles, Inc., and since 2006, he has served as a volunteer and fundraiser for the Children’s Brain Tumor Foundation.
Dr. Essig received an A.B. degree, and graduated with magna cum laude and Phi Beta Kappa honors from the Woodrow Wilson School of Public and International Affairs at Princeton University. He completed his M.B.A. and Ph.D. degrees in financial economics from the University of Chicago Graduate School of Business.
PETER J. ARDUINI has been president and chief executive officer of Integra LifeSciences since January 2012. He joined Integra in November 2010 as president and chief operating officer.
Before joining Integra, Mr. Arduini was corporate vice President and president of Medication Delivery, Baxter Healthcare. He was responsible for a $4.8 billion global division of Baxter focused on inpatient pharmaceuticals and devices. Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of senior leadership roles for domestic and global businesses, including general manager for the global imaging business. Prior to joining General Electric Healthcare, he spent four years with Procter and Gamble in sales and marketing.
Mr. Arduini’s board memberships include Advanced Medical Technology Association (ADVAMED), Bristol-Myers Squibb Company, Medical Device Innovation Consortium (MDIC), and the National Italian American Foundation. He also serves on the Board of Trustees of Susquehanna University.
Mr. Arduini received his bachelor's degree in marketing from Susquehanna University and a master's degree in management from Northwestern University's Kellogg School of Management.
KEITH BRADLEY, PH.D. has been a director since 1992.
He has been the chair of the compensation committee and is a member of the nomination and governance committee. He also currently serves as a director and member of the compensation committee of SeaSpine Holdings Corporation. Between 1996 and 2003, he was a director of Highway Insurance plc, an insurance company listed on the London Stock Exchange, and has been a consultant to a number of businesses, governments and international organizations. Dr. Bradley was formerly a visiting professor at the Harvard Business School, Wharton and UCLA, a visiting fellow at Harvard's Center for Business and Government and a professor of international management and management strategy at the Open University and Cass Business School, U.K. Dr. Bradley has taught at the London School of Economics and was the director of the School's Business Performance Group for more than six years. He received B.A. (Hons) degree from Middlesex University, and M.A. and Ph.D. degrees from the British University of Essex. Dr. Bradley is an adviser to RPH Capital, Canada. He currently serves as a director and member of the compensation committee of SeaSpine Holdings Corporation. In addition, he previously served as a director and chair of North Star Capital Management Limited and GRS Financial Solutions Limited.
RICHARD E. CARUSO, PH.D. founded the Company in 1989 and served as the Company's Chairman from March 1992 until January 2012 and as a director since March 1992. Dr. Caruso is currently the President and a member of The Provco Group, a venture and real estate investment company, an advisor to Quaker BioVentures, a medical venture capital financial investor, a member of the Board of Directors of Diasome Pharmaceuticals, LLC, a start-up company, and an advisor to NewSpring Capital and ePlanet Ventures II, both diversified venture capital financial investors. Further, he serves as the Chief Executive Officer of Smart Personalized Medicine, LLC and Chairman and Chief Executive Officer of Ceelite Technologies, LLC. Dr. Caruso served as the Company's Chief Executive Officer from March 1992 to December 1997 and also as the Company's President from September 1995 to December 1997. From 1969 to 1992, Dr. Caruso was a principal of LFC Financial Corporation, a project finance company, where he was also a director and Executive Vice President. In 2006, Dr. Caruso was named the Ernst and Young National Entrepreneur of the Year for the United States. Dr. Caruso is on the Board of Susquehanna University, The Baum School of Art and the Uncommon Individual Foundation (Founder). He received a B.S. degree from Susquehanna University, an M.S.B.A. degree from Bucknell University, a Ph.D. degree from the London School of Economics, University of London (United Kingdom), and an honorary Ph.D. degree in medical engineering from Drexel University.
BARBARA B. HILL has been a director of the company since May 2013. Ms. Hill has been an operating partner of NexPhase Capital, formerly Moelis Capital Partners, a private equity firm, since 2016. She is responsible for assessing the firm’s healthcare-related investments and providing strategic operating support for its healthcare portfolio companies.
Previous to Moelis Capital Partners, she served as chief executive officer and a director of ValueOptions, Inc., a managed behavioral health company, and FHC Health Systems, Inc., its parent company. Her other previous roles included serving as chairman and chief executive officer of Woodhaven Health Services, an institutional pharmacy company, and president and a director of Express Scripts, Inc. She was also responsible for operations nationally for Cigna HealthCare and also served as the chief executive officer of health plans owned by Prudential, Aetna and the Johns Hopkins Health System.
Currently, Ms. Hill serves as a board member and member of the compensation committee of Owens and Minor, a health care product distribution company. In addition, Ms. Hill serves as a board member and a member of the compensation committee of Omega Healthcare Investors, Inc., a Maryland real estate investment trust. Ms. Hill’s previous board memberships included St. Jude Medical and Revera Inc., a Canadian company operating seniors' facilities throughout Canada, the United Kingdom and the United States. She was previously active with the boards or committees of the Association of Health Insurance Plans and other health insurance industry groups.
Ms. Hill received her B.A. and M.S. degrees from Johns Hopkins University.
LLOYD W. HOWELL, JR. has been a director since March 2013.
Mr. Howell is an executive vice president and the chief financial officer and treasurer of Booz Allen Hamilton. Since joining the company in 1988 as a consultant, he served in a variety of leadership roles, including Civil and Commercial Group leader and client service officer of the financial services account. In 1991, he took a leave of absence from Booz Allen to complete his M.B.A. and worked at Goldman Sachs as an associate in their investment banking division from 1993 to 1995.
Mr. Howell’s board memberships include Washington Economics Club, the University of Pennsylvania’s Engineering School, and St. Albans School.
Mr. Howell holds a B.S. in electrical engineering from the University of Pennsylvania and an M.B.A. from Harvard University.
DONALD E. MOREL, Jr., PH.D. has been a director of the company since August 2013.
Dr. Morel was the former chairman and chief executive officer of West Pharmaceuticals Inc., a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. He served as president of West Pharmaceutical Services in April 2002 and became chief executive officer in June of that year. He was appointed to the board of West Pharmaceuticals in 2002 and served as the chairman of the Board of Directors from 2003 to 2015.
Dr. Morel currently serves on the Board of Directors of Catalent, Inc. and is the chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center. He is also the chairman of the Board of Trustees of the Franklin Institute and a trustee of Lafayette College. He previously served as a director of Kensey Nash Corporation, a medical device product development and manufacturing company, from March 2010 to June 2012, and was a member of its audit and compensation committees.
Dr. Morel received a B.S. in engineering from Lafayette College and an M.S. and Ph.D. in materials science from Cornell University.
RAYMOND G. MURPHY has been a director since 2009.
Mr. Murphy was formerly senior vice president and treasurer of Time Warner, Inc., responsible for all U.S. and international corporate finance, project (real estate and film) finance, cash management, foreign exchange and interest rate risk management, public debt and equity financing, real estate financing, securitization financing, banking relationships and financings, and relationships with rating agencies, as well as corporate wide real estate activities and the property/casualty risk management program. Prior to joining Time Warner, Mr. Murphy held a variety of executive leadership roles, including as senior vice president and treasurer at America Online, Inc., as senior vice president for finance and treasurer at Marriott International, Inc. He also held executive positions at Manor Care, Inc., Ryder System Inc. and W R Grace & Company.
Since 2005, Mr. Murphy has been a member of the finance committee of the Advertising Council Inc. and was the chair of the committee from 2007 until 2009. He became a member of the Board of Directors of the Advertising Council, Inc. in 2004 and served on its executive committee.
Mr. Murphy received a B.S. from Villanova University and an M.B.A. from Columbia University Graduate School of Business.
CHRISTIAN S. SCHADE has been a director since 2006.
Mr. Schade currently serves as the president and chief executive officer of Aprea Therapeutics, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53.
Prior to joining Aprea Therapeutics, Mr. Schade was the chief executive officer of Novira Therapeutics, Inc., an antiviral drug discovery company focused on first-in-class therapeutics for chronic HBV infection, until it was acquired by Johnson & Johnson. Before joining Novira Therapeutics, he served as executive vice president and chief financial officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on the clinical development of therapies for dyslipidemia. Previous to this role, Mr. Schade assumed a variety of senior leadership roles, including serving as executive vice president and chief financial officer at NRG Energy, senior vice president for administration and chief financial officer at Medarex Inc., and as managing director at Merrill Lynch, leading the European Corporate Funding Group. He also held various corporate finance and capital markets roles in New York and London for both Merrill Lynch and JP Morgan Chase & Co.
Currently, Mr. Schade serves on the Board of Directors of Indivior,plc, and Sapience Therapeutics.
Mr. Schade received an A.B. degree from Princeton University, and received an M.B.A. from the Wharton School at the University of Pennsylvania.
JAMES M. SULLIVAN has been a director since 1992.
Mr. Sullivan is a co-founder and the principal advisor at the Clover Investment Group. Between 1986 and April 2009, he held several positions with Marriott International, Inc., and its predecessor, Marriott Corp., including vice president of mergers and acquisitions, and executive vice president of Lodging Development. Prior to joining Marriott, Mr. Sullivan was chairman, president and chief executive officer of Tenly Enterprises, Inc., a privately held company operating 105 restaurants. He also held senior management positions with Harrah's Entertainment, Inc., Holiday Inns, Inc., Kentucky Fried Chicken Corp. and Heublein, Inc. He was also a senior auditor with Arthur Andersen & Co. and served as a director of Classic Vacation Group, Inc. until its acquisition by Expedia, Inc. in March 2002.
Mr. Sullivan currently serves as a member of the Board of Directors of SeaSpine Holdings Corporation.
Mr. Sullivan received a B.S. degree in accounting from Boston College and an M.B.A. from the University of Connecticut.